CellProthera Acquires Full Rights to Transendocardial Catheter Developed by Celyad Oncology

Strategic acquisition secures proprietary stem cell delivery technology as CellProthera prepares for Phase 3 clinical development in heart failure post-myocardial infarction.

Mulhouse, France – February 12, 2026 – CellProthera today announced the acquisition of the transendocardial catheter originally developed by Celyad Oncology. This acquisition is a critical step for CellProthera as it prepares to enter the pivotal Phase 3 clinical trial.  The transendocardial catheter is a key enabling technology of its therapeutic approach, delivering targeted application of proprietary processed CD34 + stem cells directly into damaged cardiac tissue. The transaction includes all intellectual property rights and associated technical documentation.

Under the terms of the agreement, the payments consist of (i) a purchase price of up to €5 million in milestone-based instalments, and (ii) future royalties on net sales. 

By securing full ownership of this catheter technology, CellProthera significantly strengthens its leadership in intramyocardial administration and achieves end-to-end integration of its value chain - from autologous stem cell manufacturing to precise cardiac delivery. Full control of this critical delivery platform positions CellProthera to optimize clinical execution, streamline development, and accelerate commercialization. Originally developed by Celyad Oncology, the catheter has demonstrated a strong safety and performance profile in more than 100 patients, ensuring accurate cell distribution while minimizing procedural risk.

“This acquisition allows CellProthera to fully own its key processes - from cell production to delivery at the damaged tissue,” said Matthieu de Kalbermatten, CEO of CellProthera. “The catheter developed by Celyad offers our patients exceptional safety and precision, ensuring targeted cell distribution in the affected areas of the heart. Novel catheter injection technology and imaging will play a central role in effective delivery during our upcoming pivotal Phase 3 trial.” 

“We are pleased to see this technology continue its journey toward clinical and patient impact,” said Michel Lussier, Co-founder and Board Member of Celyad Oncology. “CellProthera is ideally positioned to take this innovation forward, building on the promising results of its Phase 2 program and its imminent Phase 3 trial.” 

CellProthera’s proprietary therapy is designed to enhance regeneration of cardiac tissue and help improve function following severe myocardial infarction by delivering autologous stem cells directly into the affected myocardium. The integration of this proven delivery system further enhances the robustness and scalability of the Company’s clinical program. With this acquisition, CellProthera aims to consolidate its position as a leading innovator in regenerative cardiology and reinforces its long-term commitment to advancing transformative cardiovascular therapies. 

About CellProthera 

CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction. CellProthera has developed a unique GMP-compliant cell manufacturing process as well as proprietary automation technology for in vitro production of a large quantity of purified, expanded CD34+ cells. Its lead therapy ProtheraCytes®, is an autologous cell therapy targeted to regenerate various damaged tissues, including cardiac tissue. ProtheraCytes is registered as an Advanced Therapy Medicinal Product – ATMP – by the European Medicines Agency (EMA). CellProthera is headquartered in Mulhouse, France. For more information, visit www.cellprothera.com.

About Celyad Oncology

Celyad Oncology is a biotechnology company focused primarily on unlocking the potential of its intellectual property. The Company is headquartered in Mont Saint-Guibert, Belgium. For more information, visit www.celyad.com.